Fl 1039 In Bacteriuria Following Prostatectomy: A Double-Mind Comparison with Pivampicillin and Placebo

Abstract

FL 1039 is a novel β-lactam antibiotic, being a 6 β-amidinopenicillanic acid derivative. This compound was compared with pivampicillin and placebo in patients with E. coli, Klebsiella-Enterobacter, and Proteus-Providencia bacteriuria following prostatectomy. In a double-blind trial 59 patients received either FL 1039 or pivampicillin or placebo orally for a period of 12 days. After the course. 16 of 20 patients from the FL 1039 group and II of 20 from the pivampicillin group had a bacterial count less than I0⁵ organisms per milliliter of urine. Placebo had no effect. Four weeks later no difference in cure rates between the three groups could be demonstrated. No development of resistance was observed. No toxic effects were noted. FL 1039 is a promising drug in bacteriuria caused by Enterobacteriaceae.